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Abstract
Background: The idiopathic inflammatory myopathies (IIMs) are chronic autoimmune conditions, typically resulting
in proximal muscle weakness and impacting upon quality of life. Accurate measurement of IIM disease activity is
imperative for appropriate medical management and carrying out valid clinical trials. The International Myositis
Assessment and Clinical Studies Group (IMACS) “Disease Activity Core Set Measures” are the current gold-standard
of IIM disease activity assessment. Anecdotally, patients with an IIM report that the IMACS Core Set Measures and
other available methods do not necessarily capture their perceived disease activity. Investigating the patient
experiences of living with an IIM and their views on the accuracy of the IMACS Core Set Measures will provide
valuable insights for both clinical and research purposes.
Methods: Eighteen interviews with patients with an IIM were carried out and analysed thematically, using a
grounded theory approach. Experiences on living with an IIM and perceptions on the accuracy of disease activity
measurement methods were explored.
Results: Interview analysis revealed four themes: 1) fatigue, 2) pain, 3) day-to-day symptom variation, 4) limitations
of creatine kinase levels and manual muscle testing.
Conclusions: This study has provided valuable insights into patient experiences of living with an IIM. Aspects of IIM
disease activity perceived not to be wholly measured by the IMACS Core Set Measures have also been identified.
These findings have implications for future IIM clinical care and research, in particular providing justification for
research into pain, fatigue and symptom variation.
Keywords: Myositis, Qualitative, Outcome assessment, Pain, Fatigue
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: alexander.oldroyd@manchester.ac.uk
1NIHR Manchester Biomedical Research Centre, Manchester University NHS
Foundation Trust, Manchester Academic Health Science Centre, Manchester,
UK
2Centre for Musculoskeletal Research, University of Manchester, Manchester
Academic Health Science Centre, Manchester, UK
Full list of author information is available at the end of the article
BMC RheumatologyOldroyd et al. BMC Rheumatology            (2020) 4:47 
https://doi.org/10.1186/s41927-020-00146-3
Background
The idiopathic inflammatory myopathies (IIMs) are a
group of chronic autoimmune conditions that can lead
to widespread inflammation and damage [1, 2]. A num-
ber of clinical IIM subtypes are recognised, including
dermatomyositis (DM), juvenile DM (JDM), polymyositis
(PM), immune-mediated necrotizing myopathy (IMNM),
anti-synthetase syndrome (ASS), and sporadic inclusion
body myositis. A wide variety of IIM manifestations can
occur, including muscle inflammation (myositis) of
proximal limb muscles leading to weakness [3–6], skin
inflammation, interstitial lung disease and an increased
malignancy risk. The disease course is variable, with
many patients reporting unpredictable episodic exacer-
bations of symptoms and disability [7].
Living with IIMs can impact significantly on quality of
life [7–9]; this impact on quality of life being a combin-
ation of disease manifestations, requirement of repeated
medical interactions and treatment complications.
Extensive qualitative research by OMERACT has in-
vestigated the impact of living with IIM [10–13]. Focus
groups, one-on-one interviews and a Delphi survey iden-
tified a number of themes, which included 1) predomin-
ance of pain and fatigue, 2) the emotional consequence
of the disease, 3) symptom variability, 4) limitations in
participation in society, 5) impact of relationships with
healthcare providers, 6) insomnia and 7) cognitive dys-
function. Identification of these themes has informed
subsequent research and development of IIM-specific
outcome measurements, such as the Myositis Activities
Profile [14] and the Functional Index [15].
“Disease activity” is defined as the features of a disease
that are potentially reversible with treatment, such as ac-
tive myositis, whereas “disease damage” refers to per-
manent and irreversible features that are a consequence
of disease activity, such as muscle fibrosis [16]. Accurate
assessment of disease activity is imperative to allow for
appropriate medical management. A number of valid
measurements of myositis disease activity have been
combined into the International Myositis Assessment
and Clinical Studies Group (IMACS) “Disease Activity
Core Set Measures” [17], which is currently used as the
gold-standard of IIM disease activity assessment. The
IMACS Disease Activity Core Set Measures include
manual muscle strength testing (MMT), blood tests for
creatine kinase (CK) levels, the Health Assessment
Questionnaire (HAQ) (a validated measure of functional
ability), and both patient and physician “global assess-
ment” of disease activity. These measurements can be
used in both clinical and research settings when disease
activity quantification is required.
Anecdotally, many people with an IIM report that the
IMACS Disease Activity Core Set Measures, and other
clinical methods, such as MRI scanning, do not
necessarily capture their own perception of disease activ-
ity. This discrepancy between clinical measurement and
patient-perceived disease activity may result in an in-
complete quantification of disease activity, thus limiting
and misfocusing clinical interventions otherwise aimed
to improve symptoms, quality of life and function.
Investigation of the patient-perceived accuracy of IIM
disease activity assessment methods may provide in-
sights that will inform future development of new out-
come measurements or the tailoring of existing
methods. Also, further understanding of the patient-
experience can assist health care professionals to better
comprehend the impact of living with IIM.
In this study, we conducted qualitative interviews to
understand the patient experience of living with IIM and
their perceptions of the ability of currently available
methods to measure IIM disease activity accurately.
Methods
Recruitment and qualitative interviews were carried out
as part of the Myositis Physical Activity Device (Myo-
PAD) study. The study aimed to design and trial the
MyoPAD system, which entails a smartphone-based app,
allowing entry of daily PROMs, and a thigh worn accel-
erometer sensor, which allows for remote and continu-
ous characterisation of gait parameters. Results of
quantitative analysis of data collected through the Myo-
PAD study will be published separately. This paper will
report the results of analysis of qualitative interview
data, collected at the time of recruitment.
Participants were recruited from the specialist neuro-
muscular clinic at Salford Royal Hospital, Salford, UK.
Participants were invited to join the MyoPAD study if
they were aged 18 years or over, had a physician-verified
IIM diagnosis (International Myositis Classification Cri-
teria Project [18] or European Neuromuscular Centre
[19] criteria) of PM, DM, IMNM or ASS, owned their
own smartphone (Apple or Android; to allow daily app
data entry) and had regular access to their own Wi-Fi
connection (to allow frequent data transfer). Participants
unable to enter data via an app or walk independently
were excluded from recruitment. Participants unable to
converse in English were also excluded as the study did
not have capacity to conduct interviews in another
language.
All participants were invited to interviews (maximum
1 hour in duration) at their time of recruitment to the
MyoPAD Study. Participants received an information
sheet prior to the interview with a list of possible areas
of discussion. A.O. conducted all interviews, which took
place in Salford Royal Hospital’s Clinical Research Facil-
ity. Participants were given the option to attend the
interview with a partner or friend who were also invited
to contribute to the discussion where appropriate
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following verbal consent from the participant. Interviews
followed a semi-structured format with pre-prepared
interview guides (see Supplementary Material for inter-
view topic guide). Interviews were audio-recorded and
transcribed.
During the interview, participants were invited to dis-
cuss the following: their experiences of living with an
IIM, symptoms, symptom variability, perceived ability to
convey symptoms during a clinical consultation, and
views on current methods of IIM disease activity meas-
urement. Participants were also invited to discuss as-
pects of living with an IIM that they perceived to be
under-recognised or not fully assessed in clinical
consultations.
Interview transcript data was analysed thematically,
using a grounded theory approach [20]. Coding was car-
ried out by A.O. and K.H. using NVivo qualitative data
analysis software (QSR International Pty Ltd., Version
11, 2015). Initial coding formed the basis for long de-
scriptive accounts of the coded data that were circulated,
discussed and refined during analysis meetings between
A.O. and K.H. Initial codes were grouped to form core
thematic categories based on multiple sources of inter-
view data.
The Greater Manchester Central Research Ethics Com-
mittee approved the study (ref. 18/NW/0676). Informed
written consent was provided by all study participants
prior to interviews. Consent included permission to record
interviews and reproduce anonymised quotations.
Results
Eighteen (61% female) participants with a verified IIM
diagnosis took part in the interviews. Four participants
were accompanied by a friend or partner; only one part-
ner quotation contributed to theme formation. The me-
dian age of the cohort was 52 years (IQR 44, 56) with a
median IIM disease duration of 5 years (IQR 2, 6). Ana-
lysis of baseline interview data revealed four main
themes. Each theme will be discussed in turn, with ac-
companying quotations (Table 1).
Fatigue
Fatigue, as a manifestation of reduced physical endur-
ance, was the most common and prominent symptom,
and was reported by all participants (Textbox quotations
1 and 2). Activities of daily living (ADLs) were frequently
reported to be affected by fatigue. In particular, ADLs
that require sustained shoulder abduction, such as hair
drying/styling and telephone use, were frequently re-
ported to be affected (Textbox quotation 3). In contrast,
participants reported less impact upon shorter duration
tasks, such as dressing; some also reported tailoring their
ADLs to purposefully include such short duration needs
of exertion (Textbox quotation 4). The impact of fatigue
upon their ability to wash, dress or care for children was
a source of great concern for a number of participants
(Textbox quotation 5).
A number of participants reported instigating strategies
to help cope with or ameliorate their fatigue, which in-
clude planning “rest days” (Textbox quotations 6 and 7).
Fatigue was reported to be a more important symptom
compared to perceived muscle weakness, which was not as-
sociated with perceived variations of disease activity or a
factor that directly impacts upon quality of life (Textbox
quotations 2 and 8). Multiple participants explained that fa-
tigue is not commonly assessed or addressed during clinical
consultations. A reduced awareness amongst clinicians of
fatigue as an IIM-related symptom was suggested as a pos-
sible reason for this omission (Textbox quotation 9).
Travel was reported to be a particularly fatigue-
inducing activity, with a number of participants report-
ing limiting their travel to only the essential. Also, the
need to plan all aspects of travel details, such as the
presence of steps or slopes, the location of rest facilities
and the assurance that an emergency contact be avail-
able, was a source of concern and sense of limitation to
a number of participants, their partners and families
(Textbox quotation 10). This need to meticulously plan
all travel, even short distances, appeared to add to a
sense of loss of independence and their condition dom-
inating many aspects of their life.
Pain
Second to fatigue, pain was a key symptom. The character
of pain was reported in a number of different ways, includ-
ing “spasm”, “muscle burning”, “feeling like you’ve run a
marathon”, and so severe that “it does bring you to tears”,
however it was generally reported that conveying the nature
of the pain was difficult (Textbox quotation 11).
Pain was noted to be linked to carrying out physical
activities, even of low intensity. The occurrence of pain
whilst carrying out daily activities was a particularly
troublesome symptom (Textbox quotation 12). A num-
ber of participants acknowledged that pain may only be
experienced when they exceed a certain level of duration
of physical exertion, typically associated with certain
ADLs. Participants reported needing to therefore be
more purposeful and deliberate in planning and execut-
ing ADLs, choosing which were essential and which can
be postponed until they felt capable.
Day-to-day symptom variation – characterisation of good
and bad days
Symptom variation was reported by the majority of par-
ticipants. Many participants reported that symptoms,
particularly fatigue and pain, varied on a day-to-day or
even hour-to-hour basis (Textbox quotations 14 and 15).
Many participants recognised the occurrence of “good”
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1 “I would say that the fatigue has more of an effect than the pain. Sort of, I get aches but that’s not the worst but, it’s just the sort
of real exhaustion that is the worst.”
2 “Fatigue is my main component. I think for me rather than muscle weakness and rather than pain it’s fatigue, concentration and focus.”
3 “So washing my hair is not too bad and then when I’m coming to dry my hair, that can be difficult, holding my hands up.”
4 “What I’ve been able to maintain is like, short, sharp things. So if I have to do something quite quick, it doesn’t bother me.”
5 “My daughter likes her in plaits, and trying to plait her hair, that can get quite tiring, I have to rest my arms.”
6 “Then you start to do daily chores like having a shower or, in my case because I’ve got a little girl; making breakfast for her, helping
her to get dressed, ironing her uniform for school. All of those day to day things that you used to do without thinking about it;
adjusting the shower head, washing your hair.”
7 “I know tomorrow is going to be a rest day because of the drive today.”
8 “Profound weakness with my myositis seems to be much more background.”
9 “I think the fatigue side seems to be missed quite a bit, that’s never sort of talked about too much, it’s more just “what’s your
strength” and “are you breathing okay”.”
10 P12’s partner: “The logistics. Where is the toilet going to be? You know, where are the steps? You know, we have to plan
everything. Everything [PARTICIPANT] does needs careful planning, because it could be detrimental to her wellbeing.”
Pain
11 “It’s not pain, it’s a really hard one to describe and I know other people will have said the same thing to you, it’s not pain for me
it’s a muscle burning that I get. And I wouldn’t describe it as painful, I’d describe it as uncomfortable but yeah you can feel something
going on but it’s really hard to explain and burning is the nearest I can get to it.”
12 “I get, what I call proper pain and then, in my legs and arms if I lift them or try to lift anything or try to hold them up for a length
of time, washing my hair, that kind of thing, then I’ll feel like a burn like you get with extreme exercise.”
13 “I don’t feel that anyone [CLINICIANS] I’ve spoken to recognise pain as part of it.”
Day-to-day symptom variation – characterisation of good and bad days
14 “I will be fine one day, the next day I can feel absolutely terrible.”
15 “I could be tired for an hour and be fine the next hour, particularly in the early days.”
16 “There’s a hill that leads up home, and if I’m having what I call a good day I can charge up it, and then a day where I know is
a flare, I’ll stop two or three times.”
17 “But I just feel like I’ve been hit by a bus. And you just ache. But the next day everything’s okay.”
18 “I suffer greatly in the mornings, first thing. I can tell by the way I am first thing in the morning, I tend to get a grasp of how the
day is going to go.”
19 “You do tend to do far too much on the good days, and then you pay for it a couple of days later.”
20 “There’s definitely a finite resource with the fatigue effect and I know that’s very difficult to quantify.”
21 “My condition is up and down all over the place so it can almost change day on day, which is ridiculous. Family and friends,
that’s the hardest thing they struggle to get their heads around. I will be fine one day, the next day I can feel absolutely terrible.”
22 “I think doctors can’t understand either, that some days you can be quite well and other days you can be really, really bad.”
23 “On the outside we look normal, we look well, you know, everybody says, “oh you look really well” … actually if they knew what
a struggle it was for me to actually get to be somewhere … people don’t recognise the exhaustion and the tiredness that can
go with it and the effort you have to put into doing the simplest tasks.”
24 “Myositis isn’t a common condition, so people don’t really understand what it is about so, therefore they’re probably more reluctant
to ask what that is… So, it’s unknown isn’t it. Therefore, people tend to respond to unknown things with oh yeah, yeah, you’re
looking okay, that’s fine it must be difficult, but I don’t think they quite know.”
25 “A lot of people have said that they’ve come out of the doctor’s office feeling quite frustrated because they haven’t been able to
convey to the doctor that they feel the way they do.”
26 “Because I could have a really bad week in the first month after seeing the rheumatologist and then, by the time I’ve got there, I’m
quite dapper and, you know, you walk in but, there’s been them days where you are crying in pain or you just feel so fatigued and
brain fogged that…so, yeah because it’s so variable you can look totally different than you have been.”
27 “Your brain tends to remember good days...unfortunately, your brain goes back to a healthy state quite quickly.”
28 “So, I actually wrote it down in the book, sort of, what it was that started and when and how that had gone. So, I could go in
and say this is what’s happened because I knew I wouldn’t remember what to say, this is how it was.”
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and “bad” days, however these varied between partici-
pants and impacted upon their function in individual
ways, depending on their lifestyle. Good days were char-
acterised by increased physical stamina, thus allowing in-
creased fulfilment of activities of daily living (ADLs),
improved walking ability, a perception of higher energy
levels and diminished or absent pain (Textbox quotation
16). In contrast, “bad days” were characterised by higher
levels of pain and fatigue and the presence of malaise,
resulting in difficulty carrying out ADLs (Textbox quota-
tion 17). Participants commonly noted an ability to iden-
tify if they were going to experience a bad day according
to their symptoms at the time of waking (Textbox
quotation 18). A number of participants described more
severe symptoms, such as pain and fatigue, in the days
following a “good day” and suggested that this may be
due to over-exertion (Textbox quotation 19).
Energy rationing, i.e. conserving one’s own energy by
carrying out only certain physical activities, was com-
monly reported, especially by participants with longer
IIM disease durations, as a coping strategy to prevent
debilitating fatigue associated with over-exertion. A
number of participants expressed that only a certain
amount of energy was available to them each day, which,
if exceeded, would result in subsequent “bad” days char-
acterised by worsening of symptoms including fatigue
and pain. Further, the difficulty in quantifying this
amount of energy was acknowledged (Textbox quotation
20). The finite amount of energy perceived to be avail-
able for a certain day was described as a “sugar cube” by
one participant (P4), with them “constantly trying to off-
set” against physical exertion.
Symptom fluctuation was reported to be under-
recognised by both family members/friends and clinicians
(Textbox quotations 21 and 22). A number of participants
explained that this non-recognition of symptoms and
symptom variation may be due to the absence of clear vis-
ual indicators of illness or symptoms. This lead to a per-
ception of IIM being an “invisible disease” (Textbox
quotation 23). Participants explained the ensuing under-
lying frustration that non-recognition of IIM can cause, in
part due to low levels of public awareness and rarity of the
condition (Textbox quotation 24).
The combination of symptom variation, infrequent
clinical review and perception of difficulty conveying the
wide variety of symptoms was a source of concern re-
ported by many participants (Textbox quotation 25). In
particular, a number of participants recognised that the
assessment at a clinic appointment may not capture
fluctuations of disease activity since the previous assess-
ment (Textbox quotation 26). A further reported limita-
tion of infrequent clinical reviews is the difficulty to
recollect, perhaps multiple symptom fluctuations that
may have occurred months previously, with “good days”
and improved symptoms being preferentially recollected,
therefore potentially limiting the clinician’s understand-
ing of the patient experience (Textbox quotation 27). A
small number of participants reported keeping a diary of
symptoms, flare occurrence and perceived causes, thus
improving symptom variation recollection at the time of
appointment (Textbox quotation 28).
Limitations of CK levels and MMT as measurements of
disease activity
Many participants provided detailed views on their per-
ception of the ability of CK levels and MMT to assess
IIM disease activity. The majority of participants ex-
plained their experiences of changes of CK levels not




29 “I get the CK checked once every few months, but that never correlates to having a flare.”
Limitations of CK levels and MMT as measurements of disease activity
30 “My own feelings are that I quite often feel worse than the results that come back from any of the tests [CK level] really.”
31 “Although there is a three hundred limit for normal, when my CK score goes from about one-sixty, one-seventy to two-forty,
two-fifty, it is still within the normal range but I am in full flare.”
32 “I feel that because my CK levels have come down that I just feel that’s what people are happy with and because it’s all
judged on that.”
33 “I find medical professionals and different people interpret it [CK levels] in different ways.”
34 “I could walk a short distance, but if I had to keep walking then I would really struggle and probably need to go to sleep afterwards.
Like lifting an arm up, I can do it once but if I had to hold the arm up for any length of time, I wouldn’t be able to do it.”
35 “I don’t think it gives a very accurate representation of strength because I think people try really hard to resist and showing how
strong they can be, because that’s your nature isn’t it, you want to try and do well in it, but actually the effort that’s involved can
really exhaust you, and as much as anything it’s repeating those movements.”
36 “I think the fatigue side seems to be missed quite a bit, that’s never sort of talked about too much, it’s more just is what’s your
strength and off you go.”
CK creatine kinase, MMT manual muscle testing, IIM idiopathic inflammatory myopathy
Oldroyd et al. BMC Rheumatology            (2020) 4:47 Page 5 of 9
corresponding to symptom fluctuations (Textbox quota-
tion 29). Even the small number of participants who felt
that the CK was associated with their disease activity felt
that it underestimated the extent of their symptoms
(Textbox quotation 30). The comparison of an individual
CK level against the normal laboratory range was criti-
cised, with participants perceiving the comparison to
their own baseline perhaps being more appropriate
(Textbox quotation 31). Further, a number of partici-
pants perceived that clinicians may base their assessment
of IIM disease activity solely on the CK level, without
taking extra-muscular manifestations into account
(Textbox quotation 32). A number of participants also
suggested that changes of the CK level is interpreted dif-
ferently by various clinicians (Textbox quotation 33).
Drawbacks of MMT, as a measure of disease activity,
were also reported by many participants, these included dif-
fering results between clinicians, the inability of MMT to
assess fatigue on sustained muscle use and inability to cap-
ture day-to-day strength variation (Textbox quotation 34).
Participants also noted the inability of MMT to assess en-
durance, which, as described earlier, is a major source of
functional limitation. It was also reported that the MMT
assessment may vary greatly depending on other factors, in
particular patient motivation and a clinician’s prior know-
ledge of weakness (Textbox quotation 35). A perception of
clinicians relying predominantly on the MMT to assess dis-
ease activity was conveyed, with participants feeling that
hidden symptoms, such as fatigue, would be missed, as de-
scribed earlier (Textbox quotation 36).
Discussion
Our study aimed to understand the patient-reported ex-
perience of living with IIM and to explore patient per-
ceptions of the ability of currently available methods to
accurately measure disease activity. This qualitative
study has provided a number of valuable insights.
Fatigue and pain were reported to be predominant
symptoms, resulting in reduced function and impacting
upon quality of life. Our findings replicate findings re-
ported in a number of OMERACT studies, which, as
mentioned earlier, investigated patient experiences of
living with IIM and identified that both pain and fatigue
were predominant symptoms. Of the small number of
studies that have quantitatively measured fatigue and
myalgia (muscle-related pain) in IIM populations, scores
were typically high (mean 7/10 for fatigue and 4/10 for
pain in DM) [21].
In combination with infrequent clinical reviews and
perceived drawbacks of MMT and CK levels, partici-
pants felt that disease activity could not be wholly quan-
tified by their clinicians. A number of studies have
investigated the validity of MMT assessment and inter-
pretation of CK levels. Both MMT and CK levels have
been deemed to accurately represent IIM disease activity
and therefore appropriately form two of the six IMACS
Disease Activity Core Set Measures [17]. Rider et al re-
ported high levels of convergent construct validity, in-
ternal reliability and inter-rater reliability [22]. In this
study, disease activity was represented by physician glo-
bal activity score, function (HAQ) and MRI changes,
however fatigue and pain were not included. Develop-
ment and validation of quantitative IIM-specific mea-
surements of fatigue, pain and other symptom qualities,
such as day-to-day variation, in the form of patient re-
ported outcome measures could potentially enhance IIM
disease activity assessment. OMERACT have recently
recommended inclusion of pain and fatigue in the core
set for IIM clinical trial outcome measures (“life impact
area”) and measurement instrument selection will be
carried out in the near future [23]. This recognition of
the importance of patient symptoms follows changes in
2014 for rheumatoid arthritis clinical trials when OMER-
ACT added in fatigue to the Core Domain Set following
patient participant focus group input [24, 25]. Partici-
pants reported that fatigue results in difficulty carrying
out particular ADLs, such as combing hair or sustained
telephone use. However participants perceived that such
difficulties are not clearly captured or quantified in rou-
tine clinical practice. Although validated measurements
of function, such as the HAQ [26] or SF-36 [27], assess
such activities (e.g. ability to “wash and dry your body” –
HAQ), these responses are assimilated into an overall
conglomerated score, thus potentially falsely missing a
patient’s limited ability to complete such a task. Perhaps
IIM-specific outcome tools, such as the Adult Myopathy
Assessment Tool [28] or Functional Index [15], that
measure task endurance could more accurately quantify
functional limitation of ADLs.
Day-to-day symptom variation was reported by the
majority of participants; this being in contrast to the
traditional understanding of IIM-related symptoms be-
ing less variable. Regardt et al reported that symptom
variation is an important facet of the IIMs [29]. This was
in association with cognitive dysfunction, limitations in
daily activities and participation in society. To our know-
ledge, no other study has investigated the detailed varia-
tions of IIM-related symptoms in either a qualitative or
quantitative manner. It is imperative that, during a con-
sultation, clinicians caring for people with IIM are able
to understand variations of symptoms and their impact
on quality of life. Further, infrequent clinical assessment,
alongside frequent symptom variation, may risk inaccur-
ate quantification of disease activity assessment. Inaccur-
ate or selective recall may also impact consultations and
comprehensive conveyance of symptoms, as described
by our participants and reported in previous studies [30,
31]. Novel methods, such as collection of daily patient-
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reported outcome measures, may provide a solution and
allow quantification of symptom variation, for use in
both clinical and research settings. Recent development
of a smartphone-based method of daily symptom track-
ing in rheumatoid arthritis has demonstrated added pa-
tient benefit, enhancing clinical consultations and
improving symptom variability recognition [32]; devel-
opment of a similar method, tailored to the IIMs, could
potentially remedy a number of limitations described by
the participants of our study.
Finally, IIMs were felt to be an “invisible” set of dis-
eases, with limited understanding from friends, col-
leagues and clinicians being a source of concern and
social isolation. The concept of a hidden disease is
present in other chronic conditions, such as rheumatoid
arthritis [33], systemic lupus erythematosus [34] and
fibromyalgia [35]. Difficulty in communicating symp-
toms to clinicians, friends, family members and col-
leagues is common in other chronic diseases that lack
outward visibility [36, 37]. Both the hidden component
of IIM and low awareness amongst the general and
healthcare populations may further add to communica-
tion difficulties in social, professional and medical con-
versations. Again, novel continuous remote monitoring
methods may facilitate reporting of hidden disease as-
pects and enhance clinicians’ understanding. Impact of
IIM upon “participation in society” was also reported
from focus group work carried out by Regardt et al. [29]
and Chung et al reported higher levels of social isolation,
compared to rheumatoid arthritis, spinal osteoporosis
and knee osteoarthritis [38]. Social isolation and a per-
ception of lack of understanding from others is com-
monly reported in other disabling chronic conditions,
such as rheumatoid arthritis [39, 40], Parkinson’s Disease
[41] and multiple sclerosis [42].
Strengths include the novelty of carrying out a detailed
qualitative study in an IIM population with a particular
focus upon participant-perceived accuracy of disease ac-
tivity assessment methods. Another strength includes
the fact that the demographics of the population mirror
that of the general adult IIM population, thus potentially
aiding generalisability, however this may be mitigated by
recruitment bias, which is the most important potential
limitation of this study. Although appropriate for the
MyoPAD study, the exclusion criteria will have pre-
cluded certain sub-groups, such as those with more pro-
found walking disability, whose experiences of living
with an IIM may differ from our recruited cohort. Self-
selection may also have occurred, with only particularly
motivated patients agreeing to take part in one-to-one
interviews, thus potentially excluding certain sub-groups.
This potential recruitment bias may affect generalisabil-
ity of findings, therefore validation of results in other
IIM populations is warranted. Future qualitative research
that includes a cohort with varying disease activity, dis-
ease duration and additional IIM subgroups broader cul-
tural backgrounds is warranted and will provide a wider
perspective on this topic.
Our findings have the potential to influence clinical
practice in a number of ways. Clinicians should be
mindful to assess regularly and quantify, where possible,
pain and fatigue levels when reviewing IIM patients.
Regular assessment of such symptoms with a focus on
resolution as a treatment aim may influence self-
management and positively impact patient quality of life.
Clinicians should also be aware of frequent symptom
variability and ensure enquiry into variation since the
last assessment.
The predominance of pain and fatigue as major per-
ceived symptoms of IIM are an important and key find-
ing. Reporting of frequent symptom variability is also
illustrated within our study. The model of conventional
pre-planned and infrequent clinic appointments may im-
pact on accurate disease activity assessment, and thus
may not be helpful for our patients. A future research
agenda into novel methods to address these issues could
greatly enhance patient care. Other suggested research
includes identifying if reported symptoms, including
pain and fatigue, are due to IIM disease activity and/or
damage; such distinction will allow for focused develop-
ment of corresponding outcome measures.
Conclusions
In conclusion, our study has provided in depth qualita-
tive insights into the patient-experience of living with
IIM, highlighting that pain and fatigue are predominant
symptoms, alongside frequent symptom variation and
the impact of current methods of IIM disease activity as-
sessment. Consideration should now be given to captur-
ing pain and fatigue along with other routine clinical
assessments in a more frequent manner for IIM patients.
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